IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer

NCT07674615 | Not Yet Recruiting Phase 1

• 1 other identifier: OC-SG-ADC
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 1

Brief Summary

To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.

Conditions

Epithelial Ovarian Cancer; Fallopian Tube Cancers; Primary; Primary Peritoneal Carcinoma

Keywords

Ovarian cancer; TROP2; Antibody-drug conjugates

Outcome Measures

Primary Outcomes (1)

• Objective response rate

  The proportion of patients with complete response (CR) and partial response (PR) assessed by the investigator in accordance with the RECIST 1.1 criteria

  12 months

Study Arms (1)

TROP2-ADC group

EXPERIMENTAL

IMMU-132 monotherapy at a dose of 10 mg/kg administered intravenously on Days 1 and 8 of each 21-day cycle.

Drug: Sacituzumab govitecan monotherapy

Interventions

Sacituzumab govitecan monotherapy DRUG

Sacituzumab govitecan monotherapy at a dose of 10 mg/kg administered intravenously on Days 1 and 8 of each 21-day cycle.

TROP2-ADC group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years and ≤ 80 years;
• Histologically confirmed advanced or recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer;
• Recurrent patients meeting one of the following two conditions:
• Disease recurrence or progression after at least one prior platinum-based chemotherapy regimen, with disease progression occurring less than 6 months from the last dose of platinum-based chemotherapy;
• Disease recurrence or progression after at least three prior platinum-based chemotherapy regimens, with disease progression occurring ≥ 6 months from the last dose of platinum-based chemotherapy, and who are unable to receive standard platinum-based chemotherapy;
• Patients with advanced epithelial ovarian cancer presenting with hematogenous metastasis, who are unable to receive standard treatment, with an estimated life expectancy of more than 3 months but approximately not exceeding 12 months with current therapy;
• Have measurable disease per RECIST 1.1 criteria (Appendix A) or diagnosis of recurrence/disease progression per GCIG criteria;
• Known BRCA (Breast Cancer Gene) and HRD (Homologous Recombination Deficiency) status;
• Have available paraffin-embedded or fresh tumor tissue for TROP-2 testing;
• Tumor tissue TROP-2 H-score \> 200;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
• Adequate bone marrow hematopoietic function and organ function, allowing the patient to receive treatment;
• Patients must have had at least a 2-week interval from prior therapy (chemotherapy, investigational agents including small molecule inhibitors, endocrine therapy, immunotherapy, and/or radiotherapy) or major surgery;
• Patients must have had at least a 2-week interval from high-dose systemic corticosteroids (however, low-dose corticosteroids \< 20 mg prednisone or its equivalent are permitted);
• Patients must have recovered from acute toxicity due to prior therapy to Grade 1 or below;

You may not qualify if:

• Patients who have previously received topoisomerase I inhibitor therapy;
• Patients with known hypersensitivity to the study drug, its metabolites, or formulation excipients;
• Patients requiring ongoing treatment or prior use of any prohibited medications (e.g., UGT1A1 inhibitors);
• Patients with Gilbert's syndrome;
• Patients with other uncontrolled malignancies concurrently or within 5 years, whose treatment would interfere with the current therapy for recurrent ovarian cancer or affect the prognosis of this treatment. Carcinoma in situ and breast cancer (without active disease or signs of recurrence) are excluded;
• Patients with a history of clinically significant hemorrhage, bowel obstruction, or gastrointestinal perforation within 6 months prior to the start of study treatment, with an estimated life expectancy of less than 3 months;
• Patients with a history of significant cardiac disease within 6 months, such as uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure (NYHA Class III-IV), or clinically significant arrhythmias requiring antiarrhythmic therapy (except stable atrial fibrillation);
• Patients with known clinically significant active chronic obstructive pulmonary disease (COPD) or other moderate-to-severe chronic respiratory disease within 6 months;
• Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose, have all neurological symptoms returned to baseline, have no evidence of new or enlarging brain metastases, and are on a daily dose of ≤ 20 mg prednisone or its equivalent. All patients with carcinomatous meningitis are excluded regardless of clinical stability;
• Patients with uncontrolled seizure history or active neurologic disorders; Patients with known HIV-1 or HIV-2 (or HIV-1/2 antibody positive) with detectable viral load, or those taking medications that may interfere with SN-38 metabolism;
• Patients with active HBV or HCV. For patients with a history of HBV or HCV, those with detectable viral load will be excluded;
• Patients with known bleeding diathesis or active bleeding disorders;
• Patients with active ≥ Grade 2 anorexia, nausea, or vomiting, and/or signs of bowel obstruction;
• Patients with other concurrent medical or psychiatric conditions that, in the investigator's opinion, may confound study interpretation or prevent completion of study procedures and follow-up examinations;
• Patients with any unstable medical problems (including the cardiac issues mentioned above, active treatment for symptomatic pulmonary embolism, stroke, renal or hepatic insufficiency, active infection/sepsis requiring intravenous antibiotics);

Sponsors & Collaborators

• Shanghai Gynecologic Oncology Group: lead

Study Sites (1)

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, 200032, China

Location

MeSH Terms

Conditions

Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Fallopian Tube Diseases

Central Study Contacts

Yulian Chen

CONTACT

86-21-64041990; emma_serendipity@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 24, 2026
• First Posted: June 29, 2026
• Study Start: July 1, 2026
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027
• Last Updated: June 30, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)